Surface Oncology competitors

Ms. Anna Protopapas is a Chief Executive Officer at MERSANA THERAPEUTICS, INC. and is based in United States.

Steven James has over 30 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Currently, Mr. James is Chief Executive Officer and director of Pionyr Immunotherapeutics. Previously, he was president and CEO of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Mr. James was president and CEO of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and began his career at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. He serves as a trustee of Middlebridge School in Rhode Island. Mr. James is currently chairman of Antiva Biosciences and Soteria Therapeutics and a director of Allakos Inc and Ventus Therapeutics. He was formerly a director of Ocera Inc. (acquired by Mallinkrodt) and Cascadian Therapeutics (acquired by Seattle Genetics).

Jan Skvarka is a Board Member at TRILLIUM THERAPEUTICS INC and President/CEO at TRILLIUM THERAPEUTICS INC and is based in Cambridge, Massachusetts. He has worked as President/CEO at Tal Medical Inc, Partner at Bain & Company, and Manager at Pricewaterhouse Coopers (PwC). Jan attended Harvard Business School between 1998 and 1999 and University of Economics, Bratislava, Slovakia.

Dr. Randall Schatzman, Ph.D., chief executive officer and board member, joined Bolt Biotherapeutics in 2019 with over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: eptinezumab, now in registration at FDA for migraine prevention and clazakizumab, being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure. Prior to co-founding Alder, Dr. Schatzman was senior vice president of discovery research at Celltech R&D where the team discovered romosozumab which was subsequently licensed to Amgen in a 50/50 partnership. Prior to joining Celltech, he was at Syntex/Roche Bioscience where he served as preclinical team leader for Cytovene and team leader for Valcyte, both of which are now currently marketed drugs. Dr. Schatzman received his Ph.D. in Molecular Pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. Dr. Schatzman is an inventor on over 30 issued patents and is an author on more than 40 peer reviewed scientific publications.